IAMBIC THERAPEUTICS Trademark

Trademark Overview


On Tuesday, April 25, 2023, a trademark application was filed for IAMBIC THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the IAMBIC THERAPEUTICS trademark a serial number of 97905484. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, November 5, 2024. This trademark is owned by Entos, Inc.. The IAMBIC THERAPEUTICS trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

research and development in the field of computational biology, bioinformatics, and genomics; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical, medical, scientific, biotechnology, and biopharmaceutical research and development; technical scientific consultation and product development for others in the field of biotechnology and immunology; development of pharmaceuticals; research and development of pharmaceutical preparations and substances for use in clinical trials; scientific and technological services, namely, research and design in the field of computational chemistry, machine learning and artificial intelligence for use in chemistry, biology, physics, biochemistry, chemical engineering, and computer science, and design and optimization of molecules, materials, and drugs; chemistry services, namely, laboratory research in the fields of chemistry and design of new chemistry; chemistry services in the nature o...
iambic therapeutics

General Information


Serial Number97905484
Word MarkIAMBIC THERAPEUTICS
Filing DateTuesday, April 25, 2023
Status686 - PUBLISHED FOR OPPOSITION
Status DateTuesday, November 5, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, November 5, 2024

Trademark Statements


NOT AVAILABLETHERAPEUTICS
Goods and Servicesresearch and development in the field of computational biology, bioinformatics, and genomics; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; pharmaceutical, medical, scientific, biotechnology, and biopharmaceutical research and development; technical scientific consultation and product development for others in the field of biotechnology and immunology; development of pharmaceuticals; research and development of pharmaceutical preparations and substances for use in clinical trials; scientific and technological services, namely, research and design in the field of computational chemistry, machine learning and artificial intelligence for use in chemistry, biology, physics, biochemistry, chemical engineering, and computer science, and design and optimization of molecules, materials, and drugs; chemistry services, namely, laboratory research in the fields of chemistry and design of new chemistry; chemistry services in the nature of drug, and molecular discovery services, and product development services; chemical research and chemistry consultation in the field of drug and molecular development; industrial analysis and research services being scientific research in the field of drug, materials, and molecular development; technical data analysis services being technology advisory services relating to computer programs for use in chemistry, biology, physics, biochemistry, chemical engineering, computer science, and the discovery of new molecules, materials, drugs, and machine learning techniques; computer programming in the fields of molecular, materials, and drug development; computer consultancy services being computer software consultation in the field of drug, materials, and molecular development; computer software consultation services, namely, assistance and consulting in connection with the development of computer applications, databases and systems for use in the field of drug, materials, and molecular development; consulting services in the design and implementation of computer-based information systems for business, namely, provision of online information relating to computer hardware and software design in the field of drug, materials, and molecular development; creation, maintenance, hosting, and design of websites in the field of drug, materials, and molecular development; provision of online non-downloadable software for simulations for drug, materials, and molecular discovery; software as a service (SAAS) services featuring computer software platforms for use in optimizing drug, materials, and molecular discovery; platform as a service (PAAS) featuring computer software platforms for use in optimizing drug, materials, and molecular discovery; creating website based indexes of information for others using information technology for use in the field of drug, materials, and molecular development; computer graphics design services, namely, realization of computer graphics and digital imaging for use in the field of drug, materials, and molecular development; scientific research in connection with computerized automation of technical processes for use in the field of drug, materials, and molecular development; software as a services (SAAS) services in the nature of hosting cloud-based computing featuring software for optimizing the development of new molecules and designing and discovering molecules, drugs, battery materials, and other molecular products

Classification Information


International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, May 23, 2023
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameIAMBIC THERAPEUTICS, INC.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressLOS ANGELES, CA 90027

Party NameIAMBIC THERAPEUTICS, INC.
Party Type11 - New Owner Before Publication
Legal Entity Type03 - Corporation
AddressLOS ANGELES, CA 90027

Party NameEntos, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressLos Angeles, CA 90027

Trademark Events


Event DateEvent Description
Friday, April 28, 2023NEW APPLICATION ENTERED
Wednesday, June 28, 2023AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Tuesday, January 23, 2024ASSIGNED TO EXAMINER
Tuesday, May 23, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, January 23, 2024NON-FINAL ACTION WRITTEN
Tuesday, January 23, 2024NON-FINAL ACTION E-MAILED
Tuesday, January 23, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, April 1, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, April 1, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, April 17, 2024NON-FINAL ACTION WRITTEN
Wednesday, April 17, 2024NON-FINAL ACTION E-MAILED
Wednesday, April 17, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, July 16, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Tuesday, July 16, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Friday, September 13, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, September 13, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, September 13, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, September 25, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, October 16, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 5, 2024PUBLISHED FOR OPPOSITION
Tuesday, November 5, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Monday, April 1, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED